Complete Remission in All 12 Colorectal Phase 2 Cancer Trial Patients

Rather good news. Now we need to really apply it broadly to see if there is any negatives at all and just what the big stats look like.

This happens to be good news because it is unequivical.  It got them all.

Best practise tells us that this needs to be our first choice for therapy.  Afyer decades of failures, we suddenly see a cure type agency.  Where else does this apply?

Complete Remission in All 12 Colorectal Phase 2 Cancer Trial Patients

Complete Remission in All 12 Colorectal Phase 2 Cancer Trial Patients

June 8, 2022 by Brian Wang

https://www.nextbigfuture.com/2022/06/176034.html#more-176034

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

They used lab-made antibody called dostarlimab. It inhibits a protein known as programmed death receptor-1 (PD-1) found in many cancer cells. This inhibition then allows the immune system to recognize the cancer cells as harmful and target them for destruction. The drug was developed by GlaxoSmithKline, and it was given an accelerated approval by the Food and Drug Administration last year for cases of endometrial cancer linked to a mismatch repair deficiency.

The treatment exposes the cancer to the immune system.

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response.

The study involved researchers at the Memorial Sloan Kettering Cancer Center as well as Yale University, and it was sponsored by the pharmaceutical company GlaxoSmithKline.

The volunteers were all diagnosed with stage II or III rectal cancer, meaning their tumors had begun to grow larger and spread to nearby parts of the body.

New England Journal of Medicine – PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer